Cell Genesys Inc. shares dropped sharply today as the South San Francisco company said it will cut more than 200 jobs, is exploring its sale or liquidation, and stopping the late-stage trial of its prostate cancer drug.
The company (NASDAQ: CEGE) also said it was terminating the employment of Chief Medical Officer Robert Dow.
Cell Genesys shares were down 45 cents — or 73 percent — to 17 cents per share in mid-day trading.
Read the rest of this entry »
January 5th, 2009 | Posted in News, Prostate Cancer | Tags: cancer, Cell, explores, Genesys, Prostate, sale, stops, trial
Cell Genesys Inc. shares dropped sharply today as the South San Francisco company said it will cut more than 200 jobs, is exploring its sale or liquidation, and stopping the late-stage trial of its prostate cancer drug.
The company (NASDAQ: CEGE) also said it was terminating the employment of Chief Medical Officer Robert Dow.
Cell Genesys shares were down 45 cents — or 73 percent — to 17 cents per share in mid-day trading.
Read the rest of this entry »
January 4th, 2009 | Posted in News, Prostate Cancer | Tags: cancer, Cell, explores, Genesys, Prostate, sale, stops, trial